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Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019  
[COVID-19]) pandemic has presently stunted the growth of the airline industry. Despite the setbacks, 
pre-COVID-19 passenger numbers are forecasted to return by as early as 2024. As the industry recovers, 
the number of long-distance flights will surely continue to increase like it did before the pandemic. The 
incidence of venous thromboembolism (VTE) following air travel is also likely to increase. Although not 
common, the unique environment of air travel exposes individuals with particular health conditions to 
an elevated risk of acquiring VTEs. Numerous factors increasing the risk of developing VTE related 
to air travel have been identified, including inherited and acquired flight-related aspects. Non-phar-
macological approaches to reduce air travel-related VTEs involve simple foot movements, compression 
socks and stockings, intermittent pneumatic compression devices, a novel modified airline seat, and 
foot exercisers. Pharmacological methods include heparins and direct oral anticoagulants. More than 
30 reliable articles were evaluated to present the current knowledge regarding air travel-related VTEs, 
their risk factors, and prophylactic methods. Issues in research methodologies found in the literature 
were identified and discussed. Further research involving international collaboration projects is recom-
mended. The authors’ perspectives regarding long flights in previously infected COVID-19 individuals 
are also included. (Cardiol J 2021; 28, 6: xx-xx)
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Introduction
Despite the effects of the ongoing severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
(coronavirus disease 2019 [COVID-19]) pandemic, 
the airline industry is projected to recover by 
2024. New estimates from the International Air 
Transport Association predict passenger numbers 
to double by the year 2039, compared to pre- 
-COVID-19 years [1]. As new technologies allow 
for more affordable travel over long distances, 
a yearly passenger growth rate of 7% since 2015 had 
been recorded until the onset of COVID-19 [2, 3]. 
The long periods of immobility and cramped 
conditions seen in most air travelers is reflected 
in the term “economy class syndrome” [4–6]. 
Therefore, the growing number of long-range 
routes and passenger numbers is likely to in-
crease the incidence of pulmonary embolism 
caused by deep vein thrombosis (DVT) [7]. It 
is estimated that in other automotive forms of 
transport, the risk for venous thromboembolism 
(VTE) amounts to between 0.5% and 10% after 
travelling longer than 12 and 24 hours, respec-
tively [7, 8]. The findings of the article are sum-
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Reviews of medical articles relating to air 
travel-related VTE, risk factors, and prophylaxis 
were conducted. Medical journals in the English 
language were selected for review using Pub-
Med and Google Scholar. The keywords used 
included “economy class syndrome”, “pulmonary 
embolism”, “deep vein thrombosis”, “venous 
thromboembolism”, “venous thromboembolism 
prophylaxis”, and “air travel-related illness” either 
as standalone searches or in combination. Addi-
tional publications not recovered in the preliminary 
searches were reviewed and added if deemed suit-
able to the topic. Finally, 30 articles were selected 
for review. Additional literature not previously cap-
tured was added to supplement the review based 
on its relevance to the scope of interest.
Mechanism
Virchow’s triad details the conditions contrib-
uting to venous thrombosis, i.e. endothelial injury, 
venous hemodynamic changes (stasis and turbu-
lence), and hypercoagulability [9, 10]. Damage to 
the endothelium causes platelets to bind to the 
injury site, forming a hemostatic plug, which may 
become the nidus of thrombosis [9]. Two common 
causes of vascular injury include surgery and major 
trauma. Hypobaric hypoxia, low humidity, and im-
mobility are commonly seen in air travel [9, 11].
Hypobaric hypoxia and low humidity
At 10,800 m, airplanes are pressurized to create 
a livable environment, which equates to an altitude 
of between 1524 and 2134 m, and a cabin pressure of 
75.8 kPa (101 kPa AMSL) [11]. In such conditions, the 
oxygen saturation in healthy individuals can decrease 
to 90–93%, whereas in the elderly and passengers 
suffering from cardiac or pulmonary disorders, it 
may be as low as 80% [9]. Although coagulation in 
hypobaric and normobaric hypoxia conditions have 
been the subject of a number of studies, there remains 
a lack of consensus regarding thrombin formation in 
the aforementioned conditions [12].
The humidity level in an aircraft is approximate-
ly 10% (compared to sea level 30–40%) [13]. This ef-
fect is exacerbated by decreased fluid intake, which 
may result in dehydration [9]. In a simulated long 
flight study, no evidence concerning dehydration 
was found, although fluid retention corresponding to 
an approximate increase of 1 kg in body weight was 
observed [14]. An increase in urinary and plasmatic 
osmolarity associated with a low humidity combined 
Central Illustration. Graphical summary of the article’s findings on air travel-related venous thromboembolism (VTE); 
DVT — deep vein thrombosis.
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with the diuretic effect of beverages, such as coffee, 
tea, or alcohol contribute to hemoconcentration 
promoting VTE formation [9].
Immobility
The endothelium can be deprived of its non-
-thrombogenic state without direct injury [10]. Im-
mobility causes stasis, which forms a chemotactic 
gradient across the endothelium, triggering major 
leukocyte migration. Furthermore, leukocyte trap-
ping can occur between the basement membrane 
and the endothelium, resulting in endothelial 
cell separation and desquamation, which further 
leads to the exposure of subendothelial layers and 
thrombus formation [10]. Thus, the immobility of 
passengers in long-distance travel is referred to as 
“economy class syndrome” [5]. As experienced by 
passengers mainly in economy class, those in win-
dow seats would have a twofold increase in risk for 
a VTE compared to those seated by the aisle [15].
Endurance athletes
Individuals in excellent physical condition can 
also be at risk of a travel-related VTE. In particular, 
endurance athletes and long-distance runners ex-
perience repeated microtrauma, which may induce 
endothelial injury. Additionally, dehydration can 
lead to hemoconcentration while immobility during 
travel to and from events contribute to VTE for-
mation [16]. In Paget-Schrötter syndrome, heavy 
upper extremity activities can activate coagulation 
in the axillo-subclavian vein [17]. Rare iliofemoral 
DVT known as May-Thurner syndrome has been 
described in a runner [18]. Indeed, a report of 
a triathlete diagnosed with DVT upon completion 
of a half-ironman triathlon indicates that DVT risk 
factors, such as microtrauma, immobility, and dehy-
dration may also be present in this population [16].
Risk factors 
The most common risk factors for flight-relat-
ed VTEs are thrombophilic abnormalities and the 
occurrence of previous DVT [11]. Others include 
obesity (body mass index [BMI] > 30 kg/m2), 
age (> 40 years old), tall and short stature 
(> 1.90 m or < 1.60 m), chronic disease, oestro-
gen administration, female gender, pregnancy, and 
immobility [19–21]. A new risk factor for VTE is 
undoubtedly related to COVID-19 infection [22]. 
At present, data are scarce regarding the implica-
tions for long-haul flights in individuals who are 
or have previously been infected with COVID-19, 
although the coagulopathy observed in the disease 
may increase the risk of VTE [23]. Because this is 
a developing topic within the literature, the authors 
offer some perspectives in the section “COVID-19: 
Authors’ perspectives”. 
In general, although most sufferers of air 
travel-related VTEs are older, young and physi-
cally fit individuals can also be at risk [16, 24]. In 
a study, travelers’ absolute VTE risk was evalu-
ated, and the identified risks were as follows: 1/109 
for pregnant travelers, 1/140 for travelers in 
a plaster cast, 1/141 for travelers with malignan-
cies, 1/164 for travelers following a recent surgery, 
1/259 for travelers on contraceptives, and 1/405 
for female travelers on hormone replacement 
therapy [25].
Inherited factors
Inherited thrombophilias predispose individu-
als to hypercoagulable states [26]. The prothrom-
bin gene constitutes the most frequent cause of 
hereditary hypercoagulable conditions, comprising 
50–60% of VTE cases, whereas factor V Leiden 
mutations with antithrombin, and protein C and S 
represent the remainder [26]. A study showed that 
in 72% of travel-related VTE cases thrombophilic 
irregularities were present [11].
Factor V Leiden and activated protein C  
resistance 
There is an elevated VTE risk in individuals 
with factor V Leiden (FVL) (in which insensitiv-
ity to activated protein C [APC] is observed) [9]. 
Moreover, APC resistance was detected in 47% 
of individuals with travel-related VTE [11]. Thus, 
even without FVL, APC resistance constitutes a 
risk factor for VTE, and it was observed in 15% of 
patients with travel-related VTE [11].
Prothrombin G20210A
Mutations to prothrombin constitute the sec-
ond most frequently inherited thrombophilia after 
FVL [11]. Combined mutations of FVL and pro-
thrombin gene 20210A are linked with a greater 
risk of VTE [27]. In a travel-related VTE study, 
a synergistic increase in the risk for DVT was 
found in FVL individuals, although the VTE risk for 
prothrombin mutations was less pronounced [28].
Protein C and protein S
Protein C is a vitamin K-dependent anticoagu-
lant protein, circulating as a zymogen. Anticoagu-
lant effects are exerted following the activation to 
APC which, in turn, inactivates factors Va and VIIIa, 
further activating factor X for thrombin formation 
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[27]. Protein C deficiency was identified in 4.8% of 
individuals with travel-related VTE [11]. Protein S 
is a cofactor for APC and regulates clot formation 
[29]. Deficiencies of protein S were found in 7% of 
patients experiencing travel-related VTE. Protein C 
and protein S levels are decreased by vitamin K 
deficiency, warfarin, and liver failure [30].
Antithrombin
Antithrombin is an inhibitor of thrombin, 
factors IXa and Xa, and other serine proteases. 
Deficiency of antithrombin is either inherited or 
acquired. Inherited deficiencies result from muta-
tions, whereas acquired deficiencies are primarily 
caused by impaired production of viable antithrom-
bin, increased utilization, or protein losses [31]. 
Antithrombin deficiency may result in an elevated 
thrombotic risk and heparin insensitivity. In an air 
travel-related VTE study, 3 (< 2%) subjects with 
VTE suffered from antithrombin deficiencies [32].
Other
According to the literature, non-O blood groups 
have higher plasma levels of von Willebrand factor 
and factor VIII, which may lead to an elevated risk 
for thrombosis [13]. Fibrinogen gene mutation 
C10034T is known to produce variant fibrinogen 
linked with increased venous thrombosis [13]. Fur-
thermore, lupus anticoagulant, anti-b2-glycoprotein 
I, and antiprothrombin antibodies participate in 
prolonged coagulation in vitro [33].
Acquired factors
Pregnancy
Many adaptive changes occur in the hemo-
static system as the body prepares for placental 
expulsion and vascular disruption [34]. The body 
enters a state of hypercoagulability and hypofi-
brinolysis in order to prevent excessive bleeding 
[34]. Although VTE risk during pregnancy is low, 
the postpartum risk is 5 times higher than dur-
ing pregnancy [35]. However, the risk for VTE is 
estimated to be between 0.03% and 0.1% when 
the two factors, i.e. air travel and pregnancy, are 
combined [36]. Indeed, pregnant women on 4- to 
5-hour flights have a VTE risk 5 to 10 times greater 
than non-pregnant women, and the risk increases 
to 4 and 8 times in flights longer than 8 and 12 
hours, respectively [9].
Trophoblastic injury triggered by flight-related 
hypoxic conditions leading to premature birth and 
intrauterine death were reported [37]. Therefore, 
airlines have introduced restrictions on pregnant 
women, allowing travel only up to the 36th week 
of pregnancy [13]. Following findings presented 
by the Royal College of Obstetricians and Gy-
necologists, it is accepted that pregnancy is at least 
a moderate risk factor and requires further inves-
tigation [38]. Pharmacological prevention should 
also be evaluated in this group of travelers [24].
Antiphospholipid syndrome
Antiphospholipid syndrome is an autoimmune 
disorder in which antibodies against proteins are 
bound to anionic phospholipids on plasma mem-
branes [26]. Secondary antiphospholipid syndrome 
was observed in rheumatic diseases such as sys-
temic lupus erythematosus or as a standalone 
disease [26]. Although VTE occurrences were 
reported in nearly all locales of the vascular tree 
in antiphospholipid syndrome patients, the most 
frequently reported are lower extremity DVTs and 
pulmonary embolisms [39].
Chronic disease
Numerous cases of VTE are associated with 
chronic disease [19]. Chronic lung or cardiovascular 
diseases can be exacerbated by the hypoxic condi-
tions in air travel (i.e. induction of the coagulation 
system during a flight) [40]. Arthritis and inflamma-
tory bowel disease were also identified as potential 
risk factors together with neoplastic diseases and 
chronic kidney disease [9, 21]. Indeed, the death of 
New Zealand international rugby icon Jonah Lomu, 
who had been diagnosed with nephrotic syndrome, 
was suspected to be caused by a VTE shortly after 
a long-distance flight from the United Kingdom to 
New Zealand [41].
Obesity (BMI > 30 kg/m2) is a widely reported 
risk factor in several VTE studies [9, 21]. In fact, 
a relative risk of 2.4 for DVT was determined when 
comparing non-obese and obese women [42].
Other factors
MTHFR polymorphism  
and hyperhomocysteinemia
5,10-methylenetetrahydrofolate is reduced 
to 5-methyltetrahydrofolate using methylene 
tetrahydrofolate reductase (MTHFR). Methyl 
tetrahydrofolate is required in the re-methylation 
of homocysteine to methionine, a process that 
requires folate and vitamin B12 [43].
Indeed, MTHFR polymorphisms were linked 
to an increased VTE risk [27]. MTHFR compound 
mutations entail a greater risk for VTE compared 
to heterozygous, homozygous C677T, or A1298C 
variants which constitute an intermediate risk 
[44]. It has been demonstrated that geographic 
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and ethnic variations exist in the population. Ho-
mozygosity for C677T in North America is most 
prevalent in Hispanics (21–25%), followed by 
Whites (10–14%), and Blacks (1–2%, particularly 
in the USA and Brazil), whereas homozygosity for 
A1298C is found more in Whites (7–12%) followed 
by Hispanics (4–5%) and Asians (1–4%) [45]. In 
contrast, heterozygosity was not considered a risk 
factor for VTE [11].
Hyperhomocysteinemia is another important 
risk factor for initial and recurring VTE, especially 
when fasting levels exceed 20 µmol/L [46]. The 
most commonly known genetic cause of hyper-
homocysteinemia is MTHFR gene polymorphism 
[27]. Acquired hyperhomocysteinemia can stem 
from chronic renal failure, or it can be induced by 
drugs such as cyclosporine and methotrexate [11]. 
Additionally, folate, vitamin B6, and vitamin B12 
deficiencies due to a low dietary intake can also result 
in mild to moderate hyperhomocysteinemia [47].
Female gender
Female gender is an independent risk factor 
for flight-related VTE. According to Lapostolle et 
al. [6], 75% (42 of 56) of confirmed VTE patients 
were female. Additionally, a large cohort study 
found the VTE risk for females is 3 times higher 
than for men [20]. Moreover, an increased VTE 
risk is also observed in menopausal women receiv-
ing hormone replacement therapy; in individuals 
undergoing estrogen therapy, the risk of VTE is 
nearly 20 times higher [21, 48]. The use of the 
oral contraceptive pill (OCP) in healthy women 
increases VTE risk fourfold [49]. According to 
the Centers for Disease Control and Prevention, 
12.6% of women between 15 and 49 years of age 
take the OCP in the USA [50]. Worldwide, 65 mil-
lion women take the OCP, which amounts to 6% 
of all women of reproductive age [11]. Indeed, the 
increased risk of VTE events when using OCP is 
well established in the literature [49].
Flight-related
Long-distance flights are defined as lasting 
7 to 15 hours or more [51, 52]. According to the 
literature, the risk of DVT for such flights equals 
3–12% and is 3 times higher in comparison to 
shorter travels [53].
Arya et al. [51] found that long-haul flights 
(> 8 h) were associated with DVT only if one ad-
ditional risk factor was present.
Window and central seating locations are 
significant. Belcaro et al. [54] observed that 18 of 
19 thromboses were formed in subjects sitting by 
the window or in central seats. In their subsequent 
study, all 22 DVT cases (of 422 subjects) were 
reported in passengers seated by the window or 
in central seats. As for so-called “economy class 
syndrome”, the risk was the same for business and 
economy class travelers [48, 55]. Therefore, the 
term “traveler’s thrombosis” has been suggested 
as a more appropriate term [56].
As discussed previously, alcohol contributes to 
the diuretic effect, thereby increasing the risk of 
VTE. Interestingly, 66% more alcohol is consumed 
in business class than in economy class [55].
Other
A hypercoagulable state in type I and II diabe-
tes has been established. Chronic hyperglycemia 
can lead to endothelial dysfunction and is crucial 
for the progression of vascular complications in 
diabetic patients [57]. In several studies diabetes 
was frequently used as an indicator or as an exclu-
sion criterion of high-risk VTE in long-haul flights 
[58–60].
Smoking is reportedly a risk factor for travel-
-related VTE because it causes hypoxia and in-
creases blood viscosity [13, 57, 61]. In women 
taking OCPs, smoking acts synergistically in 
increasing VTE risk [62]. Interestingly, while one 
study demonstrated that smoking was unrelated 
to D-dimer development and found little evidence 
of its association with VTE, while another study 
classified smoking as a low risk for VTE [55, 63]. 
Nevertheless, cessation of smoking to decrease 
VTE risk was recommended in other studies [6, 61].
Recent surgery represents a well-described 
risk for VTE [9, 21, 64]. Surgery risk was divided 
into low (minor surgery within 3 days of a flight) 
and high risk (major surgery within 6 weeks of 
a flight) [13].
An individual with a history of previous DVT 
or pulmonary embolism is at high risk of develop-
ing VTE [6, 27].
The impact of race and ethnicity on VTE 
risk has been scarcely investigated. According to 
White and Kenan, African Americans had a notably 
higher rate of VTE, particularly following events 
which include surgery, illness, and trauma [65]. 
Pacific Islanders and Asians had between 3 and 
5 times lower risk for cancer-associated VTE, and 
idiopathic first-time symptomatic and secondary 
VTE [65]. Using Caucasians as the reference ethnic 
group for any first-time VTE risk, the less vulner-
able groups were Hispanics (50%) and Asians/ 
/Pacific Islanders (70%), whereas African Ameri-
cans were 35% more vulnerable to VTE [66]. Al-
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though genetic factors are more present in some 
ethnic groups, the data regarding air travel-related 
VTEs remain insufficient.
Prevention: Non-pharmacological
General advice on inflight exercises for travel-
ers is available from airline websites and on-board 
entertainment systems and includes stretching, foot 
exercises, standing up, removing bags from under 
the seat for more leg space, and avoiding restric-
tive clothing [59, 67]. Foot exercises increase the 
mean peak velocity in the popliteal vein and can be 
activated by frequent plantarflexion and dorsiflexion 
[68]. However, data concerning the compliance and 
efficacy of such exercises are scarce.
For higher-risk individuals, compression 
socks/stockings, intermittent pneumatic com-
pression devices, and active foot movements have 
been shown to be effective [21]. The mechanism 
is attributed to the high flow pulsatility induced by 
the vessel collapse due to distal compression (by 
muscle contraction) allowing deep veins to drain 
more readily, thereby reducing venous stasis [69]. 
External mechanical compression does not affect 
coagulation; hence, the risk of increased bleeding 
with this method is minimal.
Compression stockings
Passengers using compression stockings have 
reduced incidences of DVT and lower extremity 
edema [54]. In LONFLIT 2, the frequency of DVT 
among high-risk individuals in long-haul routes 
was reduced 18.5 times when wearing stockings 
[54]. The LONFLIT 4 Concorde Edema-SSL study 
evaluated Scholl (UK) Flight Socks (below knee, 
14–17 mmHg compression at the ankles) and found 
a distal DVT in less than 1% of the study group 
compared to 6% in the controls [54, 70]. In the 
LONFLIT 4 Concorde ECO-TRAS study, similar 
results were found regarding Sigvaris Traveno 
(Ganzoni, Switzerland) elastic stockings (below 
knee, 12–18 mmHg compression the ankles) [71]. 
Thigh-length socks were found to have equivalent 
effectiveness compared with knee-length although 
the latter has better compliance and a lower cost 
[72]. Similar efficacy was also reported in graded 
compression stockings [73].
Intermittent pneumatic compression devices
Intermittent pneumatic compression devices, 
calf muscle pump-facilitating devices, and simple foot 
movements were compared [74]. Calf muscle pump 
facilitating devices did not present a higher efficacy 
than simple foot movements, whereas the use of in-
termittent pneumatic compression devices was found 
to be justifiable for sleeping, or immobile patients 
[74]. The use of intermittent pneumatic compression 
devices on flights is restricted due to the external 
power source, size, and weight requirements; thus, 
compression stockings are preferred [75].
Modified airline seat
A modified standard airline seat (NewSit) was 
proposed, which elevates the feet, assisting leg 
mobility and allowing intermittent calf compres-
sion [76]. Improvement in venous emptying was 
observed in 23 out of 25 subjects whilst sitting for 
5 hours, in comparison to a conventional airline 
seat [76]. Currently, this is the only published paper 
concerning this technology.
Foot exercisers
Physical foot exercisers, such as the Airogym 
Exerciser (Airogym Ltd., UK) and travel footrest 
hammocks (various brands), are less common, 
although they do promote blood flow through deep 
veins [77].
Prevention: Pharmacological
Pharmacological methods aim to decrease 
coagulation and clot formation. Common drugs 
include low-molecular-weight heparin (LMWH), 
unfractionated heparin (UFH), factor Xa inhibi-
tors, direct thrombin inhibitors, and acetylsalicylic 
acid (ASA) [24, 48]. Such methods to decrease or 
prevent DVT can be employed when compression, 
or other physical methods are contraindicated, 
as in the case of severe arterial claudication, 
drug allergies, or high hemorrhage risk [78]. The 
main advantages of the pharmacological measures 
are the increased compliance when compared to 
non-pharmacological methods [78]. Crucially, for 
individuals undergoing long-term anticoagulant 
therapy with a proven prevention of recurring VTE 
(following an unprovoked first event), the same ef-
fect cannot be presumed when administering these 
medications shortly before travel [79].
Heparins
Conventional evidence-based guidelines for 
the treatment and prevention of DVT are with hep-
arins [79]. Data regarding UFH use for pre-flight 
DVT prophylaxis is scarce because it is normally 
used instead in the treatment of acute VTE in 
controlled settings due to the intensive activated 
partial thromboplastin time demands [24, 80].
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Low-molecular-weight heparin has replaced 
UFH as the drug of choice for VTE prophylaxis 
[64]. The efficacy of LMWH is well documented 
and recommended for high-risk individuals on long- 
-distance flights [81]. LMWH has certain ad-
vantages over heparin, such as a lower risk of 
heparin-induced thrombocytopenia at 0.2% vs. 
2.6%, respectively, and better pharmacokinetic 
profile [82]. In a study, a LMWH group who were 
administered 1 mg/kg of enoxaparin between 2 and 
4 hours before a long-distance flight reported 
0.61% of thrombotic events in the extremities com-
pared to 4.8% in the control group and 2.9% in the 
ASA group (p = 0.002 when compared to the two 
other groups). Additionally, recommendations for 
a single 40 mg dose of enoxaparin or 5000 IU of 
dalteparin subcutaneously prior to departure have 
also been made [24]. LMWH’s route of administra-
tion is not the most convenient, which decreases 
its compliance [83].
Direct oral anticoagulants: Factor Xa  
and direct thrombin inhibitors
Due to minimal food and drug interactions, 
direct oral anticoagulants are a safer alternative 
than the previous methods [61]. Furthermore, 
there is no evidence suggesting direct oral antico-
agulants cannot be used as prophylaxis for travel-
related VTE. However, as primary prophylaxis, 
LMWH is still preferred due to the novelty and 
thereby lack of data regarding direct oral antico-
agulants [83].
Factor Xa transforms prothrombin to thrombin 
and thus is essential for coagulation. rivaroxaban is 
a direct inhibitor of factor Xa [83]. Oral administra-
tion of 10 mg was recommended for the prevention 
of VTE [84]. Another direct factor Xa inhibitor is 
apixaban, but there are no data on its safety or 
efficacy for long-haul flight VTE prophylaxis [85]. 
An indirect factor Xa inhibitor is fondaparinux 
[86]. In comparison to LMWH, fondaparinux may 
increase the risk for fatal hemorrhage; on the 
other hand, when compared to UFH, it increases 
all-cause mortality, simultaneously reducing VTE 
events [87]. An informal cost analysis of the drug 
indicated fondaparinux to be more expensive than 
LMWH [80]. A recommendation for pre-flight 
VTE prevention is 2.5 mg subcutaneously [24]. 
Contraindications for factor Xa inhibitors are re-
nal insufficiency (creatinine clearance < 30 mL/ 
/min) and hemodialysis [24].
Dabigatran etexilate is a thrombin inhib-
itor with a similar efficacy to enoxaparin and 
a comparable safety profile to LMWH [24]. It has 
predictable pharmacokinetics, a rapid onset of 
action, and minimal drug and food interactions. 
A recommended prophylactic dosage is reported 
as 220 mg once per day [88].
Acetylsalicylic acid
Acetylsalicylic acid inhibits platelet activation 
by the inactivation of cyclooxygenase. ASA used 
in combination with stockings has proven to be 
beneficial, although very few studies support ASA 
use for VTE prophylaxis [56, 89]. Subjects of the 
LONFLIT 3 study were administered 400 mg once 
daily for 3 days, beginning the first dose 12 hours 
prior to the flight. The results indicated a small 
decrease of 3.6% in subjects with DVT compared 
with 4.8% in the control group; however, this result 
was not statistically significant [81]. The efficacy 
of ASA as a standalone drug in VTE prevention is 
doubtful; hence, the American College of Chest 
Physicians have advised against its use for throm-
boprophylaxis [56].
Discussion
It is generally accepted that air travel is related 
to VTE [53, 90, 91]. However, the issue of het-
erogeneity in the literature remains problematic, 
although explicable. Despite various definitions of 
a “long-distance” flight, the research performed 
has been extensive in methodology, variables, 
sampled populations, and locations, offering vari-
ous opinions on the inclusion or exclusion criteria 
[51, 92]. Major papers and findings are summarized 
in Table 1. 
The conundrum of air travel-related VTE 
is that it constitutes a multifactorial disease [9]. 
Distance or length traveled, individual variables, 
air travel conditions, passenger behaviors during 
travel, and recent events prior to travel such as 
trauma and surgery, all interact to produce differ-
ent outcomes [56]. Thus, it is very challenging to 
identify the exact factors resulting in travel-related 
VTE.
The great variety of study designs in the 
literature is encouraging [56]. However, the vari-
ability in the study protocols has in some cases 
impeded subsequent meta-analyses [53]. Numer-
ous studies do not meet the criteria for inclusion 
to meta-analyses (such as the MOOSE guidelines) 
and thus are unable to contribute to the existing 
literature [53, 93]. Chandra et al. [53] reported is-
sues with study design, in particular regarding the 
use of control participants. The idea that control 
participants should be similar to the case patients is 
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erroneous because individuals who develop VTEs 
or DVTs will always have more risk factors for the 
disease than those who remain disease-free [53]. 
This selection bias leading to the underrepresenta-
tion and, therefore, incorrect conclusions requires 
attention for future studies [53].
The literature shows a reliance on the D-dimer 
to determine the presence of DVT. For instance, 
in the New Zealand Air Traveler’s Thrombosis 
study, only participants with elevated D-dimer 
scores were included for further investigation 
[89]. Having a high sensitivity, D-dimer levels are 
well established, although the false positive rate 
for other conditions compromises their specificity 
[94]. Furthermore, a third of the 878 subjects had 
been administered ASA. Hence, it was suggested 
that either the patients taking ASA were at high-
risk for VTE, or the ASA falsely elevated D-dimers 
due to gastritis [55]. In another study, 12 subjects 
were evaluated for asymptomatic thrombosis 
detected by ultrasound. In 6 of these subjects, no 
elevation in D-dimer was observed. However, the 
authors note that the short half-life of D-dimers 
(6 h) and the long time (up to 48 h) between the 
Table 1. Major papers on air travel-related venous thromboembolism (VTE).
Authors Year Study type Findings
Ferrari et al. [90] 1999 Case control Travel is a risk factor for VTE
Kraaijenhagen et al. [91] 2000 Case control No association between VTE  
and long-distance travel
Arya et al. [51] 2002 Case control DVT risk only increased in long-haul travelers  
if additional risk factors are present  
— prophylaxis recommended
Martinelli et al. [32] 2003 Case control Air travel doubles the risk for VTE,  
and the presence of thrombophilia or oral  
contraceptives increases the risk  
16 and 14 times, respectively
Schwarz et al. [102] 2002 Cohort pilot Passengers with isolated calf vein thrombosis  
reported other risk factors for thrombosis
Schwarz et al. [48] 2003 Cohort Flights longer than 8 hours double the risk for  
isolated calf muscle venous thrombosis
Lapostolle et al. [6] 2001 Retrospective A greater distance traveled is a significant  
contributor to air travel-related PE
Pérez-Rodríguez et al. [52] 2003 Retrospective Air travel is a risk factor for VTE, and its  
incidence increases with the journey duration
Scurr et al. [7] 2001 Randomized trial Asymptomatic DVT in up to 10% of  
long-haul air travelers. Wearing compression  
stockings associated with a reduction  
in asymptomatic DVT
Belcaro et al. LONFLIT 1 [59] 2001 Cross-sectional Flight related DVTs were found in individuals  
who presented a high risk or sitting in the  
window and central seats
Belcaro et al. LONFLIT 2 [59] 2001 Randomized trial Compression therapy (stockings) decreased  
DVT incidence in long-haul flights
Cesarone et al. LONFLIT 3 [81] 2002 Randomized trial LMWH use almost eradicated  
thrombotic events
Belcaro et al. LONFLIT 4  
Concorde Edema-SSL [103]
2002 Randomized trial Scholl Flight Socks are effective in controlling  
edema and reducing DVT incidence in low  
to medium risk subjects on long-haul flights
Cesarone et al. LONFLIT 4  
ECO-TRAS [71]
2003 Randomized trial Sigvaris Traveno Stockings are effective in  
controlling edema in long-haul flights
Cesarone et al. LONFLIT 4  
Concorde DVT Edema [104]
2003 Randomized trial Kendall Travel Socks are effective in controlling 
edema and reducing DVT incidence in  
low- and medium-risk subjects
Belcaro et al. LONFLIT 5  
JAP [70]
2003 Randomized trial Scholl Flights Socks are effective in reducing  
DVT incidence in high-risk subjects
DVT — deep vein thrombosis; LMWH — low-molecular-weight heparin; PE — pulmonary embolism
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end of the journey and collecting blood samples 
could be contributing factors [7]. Schwarz et al. 
[48] noted 11 out of 27 DVTs, or isolated calf mus-
cle vein thromboses, to have elevated D-dimers. 
In fact, the high negative predictive value of the 
D-dimer was reportedly so high that it has been 
clinically used to exclude DVT in low-risk patients 
[95]. Even though the role of D-dimers as a VTE 
marker has been well investigated, its continued 
role should be revised [28, 55].
Although using venography to detect DVTs is 
considered a gold standard by some researchers, 
others consider its use unethical in asymptomatic 
patients. Therefore, alternative methods, such as 
duplex ultrasonography, have also been used [7]. 
However, there is a potential to underestimate 
thromboses due to the specificity, which is report-
edly between 79% and 99% [7]. Furthermore, 
duplex ultrasonography sensitivity and specificity 
decrease for distal DVT when compared to veno-
graphy [94].
The variability in the time in which the DVT 
presents (from during the flight to several weeks 
after) poses a challenge for capturing data out-
side the normal ranges [53]. Optimal timing of 
ultrasound scans then should be considered when 
investigating travel-related VTE. In the BEST 
study, compressive ultrasonography (CUS) was 
used in addition to D-dimers to improve detection 
accuracy. However, most participants declined the 
CUS after the journey. Only half of the participants 
who presented elevated D-dimer agreed to a CUS. 
Additionally, because the scans were performed 
on arrival, it was not possible to detect develop-
ing thrombi. Interestingly, 90% of subjects with 
elevated D-dimers reported no VTE symptoms in 
the follow-up 6 months later [55].
Participant attrition can affect the statistical 
power of the study. Because the literature largely 
depends on volunteer recall, many subjects do not 
continue with subsequent phases of the research. 
Dropouts due to flight connection problems or 
other non-medical issues have the potential to af-
fect results, depending on the study design, e.g. in 
LONFLIT 1 and 2, out of the original 1663 partici-
pants, 1577 subjects did not complete the study [59, 
92, 96]. Another study by Belcaro et al. [60] showed 
that only 198 out of 244 individuals completed the 
study due to logistical problems. Critically, the size 
of the dropout effect may be difficult to determine. 
Although it is conceivable that participants will be 
tired after the journey and dropouts may occur for 
a multitude of reasons, every possibility to retain 
subjects should be explored.
Recall bias can be managed with careful study 
design [28, 53]. Although difficult to eliminate, 
recall bias from questionnaires can be decreased 
with clear guidelines and timely administration of 
questionnaires [32]. Particular items, such as the 
exact amount of water/alcohol/fluid intake and the 
amount of inflight exercise, are available only from 
the most determined research subjects.
The varying length and duration of flights may 
need to depend on randomization of data for mean-
ingful statistics [92]. The unpredictable nature of 
flights and airborne delays or re-routing, which 
can be difficult to report accurately, may result in 
inaccuracies in the subsequent analyses.
It is vital then to conduct a series of large in-
ternational collaborations where uniformity in data 
collection methodology and consistency in study 
designs can definitively capture the correct data. To 
date, the BEST study is an example of such a col-
laboration, where subjects flew directly from point 
A to point B, with data collection at both locations 
eliminating the concern regarding stopovers [6, 92]. 
In terms of recall biases, the aforementioned large-
scale studies could even involve airlines through 
flight attendants, who could remind the participants 
to record the datapoints at the best junctures.
Pre- or post-surgery considerations
Endothelial damage can be a proponent for 
platelet aggregation, causing thrombus formation 
and increasing the risk of VTE after surgery. It 
is possible that the danger of VTE is enhanced 
when surgery and long-haul travel are combined. 
In fact, the risk of VTE increases nearly 20 times 
in passengers who had a surgery within a 3-month 
period [25]. Conversely, in a study involving 1465 
total joint arthroplasty patients, 220 traveled by 
air at a mean of 2.9 days after the surgery and 
demonstrated no differences between flying and 
non-flying patients. The study concluded that air 
travel following total joint arthroplasty is safe 
[97]. Furthermore, another study also found that 
preoperative air travel did not influence the risk 
of VTE after total hip and knee arthroplasty [98].
A case report described a 37-year-old male 
who traveled from Europe to the USA for elective 
pelvic surgery. Six days postoperatively, the man 
died from an acute pulmonary embolism despite 
having heparin prophylaxis [99]. The authors sug-
gested he had developed a DVT during travel and 
the symptoms appeared following the surgery. 
However, the patient did present additional VTE 
risk factors, including heavy smoking, obesity, and 
dehydration due to pre-operative preparations [99]. 
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Indeed, long-haul travel prior to a major surgery 
increases the risk of perioperative VTE [99].
COVID-19: Authors’ perspectives
When is it safe to travel long distances by 
air given a previous COVID-19 infection? The 
thrombotic risk in COVID-19 is well documented, 
and in many cases, it is a determinant of disease 
severity or fatality [100, 101]. However, to begin 
answering this question, the issue of the severity 
with which the individual suffered from the disease 
should first be evaluated. The introduction of vac-
cinations brings yet another set of uncertainties 
to the equation, which adds much complexity to 
the issue. This question unfortunately cannot be 
answered scientifically without data and large-scale 
studies, as described in the previous sections. 
Given the fluidity of the situation and the amount 
of new information being learned about the disease 
every week, the authors are hesitant and reluctant 
to provide any real opinions. 
In any case, exercising the rule of “best 
judgment” and conservative management, we 
recommend that those previously infected with 
COVID-19 wait at least 6 months after resolu-
tion of the disease. This includes cases of long 
COVID-19 where it is not advisable to travel at all 
until disease-free. Furthermore, flights in these 
individuals should be limited to less than 6 hours 
duration. Should the essential need for longer 
journeys arise, it is advisable to arrange multi-stop 
journeys with a travel break in between. Lastly, the 
general methods of VTE prevention as described 
in this review should be strictly followed: 
 — Take pharmacological prophylaxis under direc-
tion of the individual’s physician;
 — Choose an aisle seat if possible and/or seat 
with more legroom;
 — Strictly adhere to on-board airline guidance 
regarding DVT prevention strategies, i.e. 
calf exercises, periodic foot movements, and 
frequent ambulation;
 — Drink plenty of water and refrain from alcohol, 
coffee, or other diuretics before, during, and 
after the flight;
 — Purchase and wear recommended compressive 
flight stockings as directed.
Conclusions
Great interest in the literature regarding air 
travel-related VTE reflects global trends. The con-
ditions in which people travel by air over long dis-
tances are likely to facilitate VTE formation, most 
frequently in higher-risk individuals with predispos-
ing factors. As such, preventative measures should 
be evaluated to decrease the possibility of develop-
ing VTE in at-risk individuals. It is likely that as 
a result of lockdowns and travel restrictions imposed 
throughout the pandemic, the post-COVID-19 
era may well see a sharp rise in air travel as bor-
ders reopen. Because long-distance airline travel 
is mostly international, larger prospective research 
on an international level should be supported. In 
particular, studies relating to individuals with post 
SARS-CoV-2 infection, infection severity, and vac-
cination effects will be of exceptional value.
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